In the News
April 2, 2020
A Message from the CEO on the COVID-19 Initiative
Chimeron Bio's CEO Dr. Jolly Mazumdar speaks in more detail about the company's COVID-19 vaccine program.
NEWS: Chimeron Bio Launches Vaccine Program for COVID-19
Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.
Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.
How we do it
Our ChaESAR Platform
Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.
Why we do it
Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs
We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.
The Latest from Chimeron Bio
From Our Blog
February 12, 2020
Tackling Polygenic Diseases – Chimeron Bio’s Combination RNA Drug Platform is Pushing the Field
See how ChaESAR particles are designed to & can package multiple genes & RNA types (mRNA, small oligos) within the same particle & maintain tissue tropism.
Are you passionate about science and making an impact?
We’re looking for talented individuals to join our team.